Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden

SUMMARY: Romosozumab is a novel bone-building drug that reduces fracture risk. This health economic analysis indicates that sequential romosozumab-to-alendronate can be a cost-effective treatment option for postmenopausal women with severe osteoporosis at high risk of fracture. PURPOSE: To estimate...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Osteoporos Int
Egile Nagusiak: Söreskog, E., Lindberg, I., Kanis, J.A., Åkesson, K.E., Willems, D., Lorentzon, M., Ström, O., Berling, P., Borgström, F.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer London 2021
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7929944/
https://ncbi.nlm.nih.gov/pubmed/33409591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-020-05780-8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak